<DOC>
	<DOCNO>NCT00275054</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Drugs use chemotherapy , fludarabine cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Sometimes cancer may need treatment progress . In case , observation may sufficient . It yet know whether give rituximab together fludarabine cyclophosphamide effective observation alone treat chronic lymphocytic leukemia . PURPOSE : This randomized phase III trial study rituximab , fludarabine , cyclophosphamide see well work compare observation alone treat patient stage 0 , stage I , stage II B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Rituximab , Fludarabine , Cyclophosphamide Observation Alone Treating Patients With Stage 0 , Stage I , Stage II Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare effect , term event-free survival , defer versus immediate treatment rituximab , fludarabine , cyclophosphamide patient previously untreated Binet stage A chronic lymphocytic leukemia high risk disease progression . - Investigate define new prognostic staging system patient Binet stage A chronic lymphocytic leukemia . Secondary - Compare time progression Binet stag B C patient treat regimen . - Compare overall progression-free survival patient treat regimen . - Compare quality life patient treat regimen . - Compare time treatment patient treat regimen . - Analyze pharmacoeconomics regimens patient . - Determine overall response rate ( partial complete ) patient include early treatment arm . - For patient include early treatment arm complete remission , determine percentage achieve complete molecular remission use clone-specific CDR-III region follow-up parameter . - Determine duration response patient include early treatment arm . - Determine adverse event related treatment/safety treatment . OUTLINE : This randomize , multicenter study . Patients stratify accord risk factor profile ( &lt; 2 risk factor [ low risk ] v â‰¥ 2 risk factor [ high risk ] ) . Low-risk patient assign arm II . High-risk patient randomize 1 2 treatment arm . - Arm I : Patients receive rituximab IV day 1 , fludarabine IV day 1-3 , cyclophosphamide IV day 1-3 . Treatment repeat every 28 day 6 course . - Arm II : Patients undergo observation disease progression . PROJECTED ACCRUAL : A total 600 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Established diagnosis Bcell chronic lymphocytic leukemia First diagnosis within 12 month inclusion study Previously untreated disease Binet stage A disease ( Rai stage 0 , I , II ) PATIENT CHARACTERISTICS : Life expectancy &gt; 6 month ECOG performance status 02 Willingness accept contraception ( randomized arm I ) duration therapy 12 month thereafter Negative serum pregnancy test All parameter risk stratification ( lymphocyte doubling time , cytogenetics , unmutated IgVH , serum thymidine kinase level &gt; 10 ) present PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , antibody treatment No concurrent chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
</DOC>